SEMAGLUTIDE WEEK 1-12 BUNDLE - AN OVERVIEW

The demo obtained each its Main endpoints, with semaglutide 2.4 mg demonstrating statistically major and remarkable improvements in liver fibrosis with no worsening of steatohepatitis, and also resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH compared to placebo.1The subsequent critical adverse reactions ar